Determination of Significant Pretreatment Factors that Predict Survival in Indonesian Subjects with Breast Cancer

Citra Aryanti; Putu Anda Tusta Adiputra; Tjokorda GB Mahadewa; Sri Maliawan; I. N. W. Steven Christian; Ida Bagus Made Suryawisesa

doi:10.3889/oamjms.2021.7503

Authors

Citra Aryanti Department of Surgery, Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia
Putu Anda Tusta Adiputra Department of Surgery, Division of Surgical Oncology, Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia
Tjokorda GB Mahadewa Department of Neursurgery, Division of Surgical Oncology, Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia https://orcid.org/0000-0002-4445-4085
Sri Maliawan Department of Neursurgery, Division of Surgical Oncology, Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia
I. N. W. Steven Christian Department of Surgery, Division of Surgical Oncology, Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia
Ida Bagus Made Suryawisesa Department of Surgery, Division of Surgical Oncology, Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.7503

Keywords:

Breast cancer, Predictive factors, Indonesia, Retrospective studies

Abstract

BACKGROUND: The determination of the pre-treatment’s survival predictive factors is very important as a basis for clinicians to educate and determine appropriate management for patients.

AIM: This study aimed to determine the pre-treatment risk factors that predict survival in Indonesian subjects with breast cancer.

METHODS: This was a cohort retrospective study conducted on breast cancer subjects visiting Sanglah General Hospital from 2016 to 2020. Data were collected from Indonesian Cancer Registry medical records such as age, tumor size, lymph nodes, metastasis, Karnofsky score, serum CA15-3 level, hormonal receptor status (ER/PR), HER2, Ki-67, LVI, tumor-infiltrating lymphocytes, cell type, histological grade, and survival status until December 2020. Data were tabulated and analyzed statistically using SPSS 25.0.

RESULTS: The median survival of breast cancer in this study was 47 months (SD 4.851). Majority of breast cancer subjects with mortality outcome were those who had Karnofsky score less than 70, tumor size ≥5 cm with infiltration, presence of contralateral lymph node, with metastasis, serum CA15-3 level >25 IU/mL, negative hormonal receptor, negative HER2 receptor, Ki67 higher than 14, negative lymphovascular invasion, negative tumor-infiltrating lymphocytes, and histological Grade 3. Age and pathological type were not significantly differed the breast cancer outcome.

CONCLUSION: There were significant effects of tumor size, KGB status, metastasis, serum CA15-3 levels, hormone receptor, HER2 receptor, Karnofsky score, lymphovascular invasion, tumor-infiltrating lymphocytes, and histological grade on breast cancer subjects’ survival.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. http://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660

Kementrian Kesehatan RI. Beban Kanker di Indonesia. Kementrian Kesehatan RI: Pusat Data dan Informasi; 2019.

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-86. http://doi.org/10.1093/ jnci/81.24.1879 PMid:2593165 DOI: https://doi.org/10.1093/jnci/81.24.1879

Sopik T, Narod SA. The relationship between tumour size, nodal status, and distant metastases: on the originis of breast cancer. Breast Cancer Res Treat. 2018;170(2):647-56. http://doi.org/10.1007/s10549-018-4796-9 PMid:29693227 DOI: https://doi.org/10.1007/s10549-018-4796-9

Chu WG, Ryu DW. Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer. Ann Surg Treat Res. 2016;90(2):57-63. http://doi.org/10.4174/astr.2016.90.2.57 PMid:26878012 DOI: https://doi.org/10.4174/astr.2016.90.2.57

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973-9. http://doi.org/10.1200/JCO.2003.09.099 PMid:12743151 DOI: https://doi.org/10.1200/JCO.2003.09.099

Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, et al. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer. 2019;10(12):2635-42. http://doi.org/10.7150/jca.32453 PMid:31258771 DOI: https://doi.org/10.7150/jca.32453

Zhang S, Zhang D, Gong M, Wen L, Liao C, Zou L. High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer. BMC Cancer 2017;17(1):335. http://doi.org/10.1186/s12885-017-3338-x PMid:28514957 DOI: https://doi.org/10.1186/s12885-017-3338-x

Wang K, Xu J, Zhang T, Xue D. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Oncotarget. 2016;7(28):44288-98. http://doi.org/10.18632/oncotarget.9988 PMid:27329588 DOI: https://doi.org/10.18632/oncotarget.9988

Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23-31. http://doi.org/10.4137/CPath.S31563 PMid:26740749 DOI: https://doi.org/10.4137/CPath.S31563